S&P 500   3,982.50 (+0.78%)
DOW   32,382.34 (+0.43%)
QQQ   308.69 (+0.89%)
AAPL   158.86 (+0.93%)
MSFT   271.66 (-0.21%)
META   200.78 (+1.50%)
GOOGL   104.84 (+3.58%)
AMZN   99.92 (+2.26%)
TSLA   195.61 (+6.74%)
NVDA   260.40 (+0.54%)
NIO   9.27 (+5.94%)
BABA   83.40 (+2.96%)
AMD   95.56 (-1.29%)
T   18.48 (-0.05%)
F   11.77 (+5.28%)
MU   58.30 (+1.15%)
CGC   1.98 (+6.45%)
GE   92.68 (+3.07%)
DIS   96.34 (+2.25%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.85 (+3.61%)
NFLX   305.21 (+0.03%)
S&P 500   3,982.50 (+0.78%)
DOW   32,382.34 (+0.43%)
QQQ   308.69 (+0.89%)
AAPL   158.86 (+0.93%)
MSFT   271.66 (-0.21%)
META   200.78 (+1.50%)
GOOGL   104.84 (+3.58%)
AMZN   99.92 (+2.26%)
TSLA   195.61 (+6.74%)
NVDA   260.40 (+0.54%)
NIO   9.27 (+5.94%)
BABA   83.40 (+2.96%)
AMD   95.56 (-1.29%)
T   18.48 (-0.05%)
F   11.77 (+5.28%)
MU   58.30 (+1.15%)
CGC   1.98 (+6.45%)
GE   92.68 (+3.07%)
DIS   96.34 (+2.25%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.85 (+3.61%)
NFLX   305.21 (+0.03%)
S&P 500   3,982.50 (+0.78%)
DOW   32,382.34 (+0.43%)
QQQ   308.69 (+0.89%)
AAPL   158.86 (+0.93%)
MSFT   271.66 (-0.21%)
META   200.78 (+1.50%)
GOOGL   104.84 (+3.58%)
AMZN   99.92 (+2.26%)
TSLA   195.61 (+6.74%)
NVDA   260.40 (+0.54%)
NIO   9.27 (+5.94%)
BABA   83.40 (+2.96%)
AMD   95.56 (-1.29%)
T   18.48 (-0.05%)
F   11.77 (+5.28%)
MU   58.30 (+1.15%)
CGC   1.98 (+6.45%)
GE   92.68 (+3.07%)
DIS   96.34 (+2.25%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.85 (+3.61%)
NFLX   305.21 (+0.03%)
S&P 500   3,982.50 (+0.78%)
DOW   32,382.34 (+0.43%)
QQQ   308.69 (+0.89%)
AAPL   158.86 (+0.93%)
MSFT   271.66 (-0.21%)
META   200.78 (+1.50%)
GOOGL   104.84 (+3.58%)
AMZN   99.92 (+2.26%)
TSLA   195.61 (+6.74%)
NVDA   260.40 (+0.54%)
NIO   9.27 (+5.94%)
BABA   83.40 (+2.96%)
AMD   95.56 (-1.29%)
T   18.48 (-0.05%)
F   11.77 (+5.28%)
MU   58.30 (+1.15%)
CGC   1.98 (+6.45%)
GE   92.68 (+3.07%)
DIS   96.34 (+2.25%)
AMC   4.41 (+3.28%)
PFE   40.43 (-0.93%)
PYPL   75.85 (+3.61%)
NFLX   305.21 (+0.03%)
NASDAQ:ASRT

Assertio - ASRT Stock Forecast, Price & News

$6.00
+0.22 (+3.81%)
(As of 03/21/2023 01:45 PM ET)
Add
Compare
Today's Range
$5.86
$6.05
50-Day Range
$3.54
$6.66
52-Week Range
$1.86
$7.00
Volume
818,299 shs
Average Volume
1.96 million shs
Market Capitalization
$333.48 million
P/E Ratio
3.37
Dividend Yield
N/A
Price Target
$7.50

Assertio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.4% Upside
$7.50 Price Target
Short Interest
Healthy
9.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Assertio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
37.25%
From $0.51 to $0.70 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

110th out of 988 stocks

Pharmaceutical Preparations Industry

34th out of 482 stocks


ASRT stock logo

About Assertio (NASDAQ:ASRT) Stock

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

ASRT Stock News Headlines

StockNews.com Upgrades Assertio (NASDAQ:ASRT) to Buy
Assertio (NASDAQ:ASRT) Downgraded to Hold at StockNews.com
This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
Stocks For Smart Investors
This under-the-radar stock is in the right industry at the perfect time.
4 Stocks to Buy for Under $8 in 2023
Assertio Holdings Scores With New Broadly-Covered Asset
Are Medical Stocks Lagging Assertio (ASRT) This Year?
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

ASRT Company Calendar

Last Earnings
11/04/2021
Today
3/21/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASRT
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+29.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$109.63 million
Pretax Margin
19.95%

Debt

Sales & Book Value

Annual Sales
$156.23 million
Cash Flow
$2.95 per share
Book Value
$4.67 per share

Miscellaneous

Free Float
54,190,000
Market Cap
$321.25 million
Optionable
Optionable
Beta
1.38

Key Executives

  • Daniel A. PeisertDaniel A. Peisert
    President, Chief Executive Officer & Director
  • William Iskos
    Senior Vice President-Operations
  • Paul SchwichtenbergPaul Schwichtenberg
    Chief Financial Officer & Senior Vice President
  • Ajay PatelAjay Patel
    Chief Accounting Officer & Senior Vice President
  • Sam Schlessinger
    Senior Vice President & General Counsel













ASRT Stock - Frequently Asked Questions

Should I buy or sell Assertio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings
or view top-rated stocks.

What is Assertio's stock price forecast for 2023?

3 analysts have issued 1 year target prices for Assertio's stock. Their ASRT share price forecasts range from $7.00 to $8.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts price targets for ASRT
or view top-rated stocks among Wall Street analysts.

How have ASRT shares performed in 2023?

Assertio's stock was trading at $4.30 at the beginning of 2023. Since then, ASRT stock has increased by 34.4% and is now trading at $5.78.
View the best growth stocks for 2023 here
.

Are investors shorting Assertio?

Assertio saw a drop in short interest in February. As of February 28th, there was short interest totaling 5,360,000 shares, a drop of 43.2% from the February 13th total of 9,440,000 shares. Based on an average trading volume of 1,590,000 shares, the days-to-cover ratio is currently 3.4 days.
View Assertio's Short Interest
.

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ASRT earnings forecast
.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.12. The business earned $25.47 million during the quarter, compared to analyst estimates of $22.04 million. Assertio had a net margin of 70.17% and a trailing twelve-month return on equity of 72.98%. During the same period in the previous year, the business posted ($0.36) EPS.

What ETF holds Assertio's stock ?

Hartford Multifactor Small Cap ETF holds 55,110 shares of ASRT stock, representing 0.74% of its portfolio.

What guidance has Assertio issued on next quarter's earnings?

Assertio updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$38.00 million, compared to the consensus revenue estimate of $37.59 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

What is Assertio's stock symbol?

Assertio trades on the NASDAQ under the ticker symbol "ASRT."

Who are Assertio's major shareholders?

Assertio's stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.95%), Renaissance Technologies LLC (1.71%), First Eagle Investment Management LLC (1.42%), Marshall Wace LLP (1.38%), Two Sigma Investments LP (1.17%) and American Century Companies Inc. (0.93%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Group LP Cr, James L Tyree, Karen A Dawes and Paul Schwichtenberg.
View institutional ownership trends
.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assertio's stock price today?

One share of ASRT stock can currently be purchased for approximately $5.78.

How much money does Assertio make?

Assertio (NASDAQ:ASRT) has a market capitalization of $321.25 million and generates $156.23 million in revenue each year. The company earns $109.63 million in net income (profit) each year or $1.78 on an earnings per share basis.

How can I contact Assertio?

Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The official website for the company is www.assertiotx.com. The company can be reached via phone at (224) 419-7106, via email at investor@assertiotx.com, or via fax at 510-744-8001.

This page (NASDAQ:ASRT) was last updated on 3/21/2023 by MarketBeat.com Staff